Assessment of the level of PD-L1 protein expression on gastric cancer material using the new clone PBM-1A4 and comparison with clones 22C3, SP142, SP263

Abstract

BACKGROUND: The study of the properties of immunotherapeutic markers is a popular and promising area in oncology. One of the most studied targets of immunotherapy is the ligand of the programmed cell death protein 1 (PD-L1). Currently, diagnostic kits for determining PD-L1 expression in tumors are manufactured overseas. To ensure the technological sovereignty of the Russian Federation in medical technologies, research with a domestic clone of PD-L1 antibodies and comparison of the results with already validated analogs are necessary.

AIM: To validate a domestic clone of an antibody to PD-L1 (PBM-1A4) , determine the relationship of the reaction with clinical and morphological parameters, and compare with clones SP142, SP263, and 22C3 in gastric cancer.

MATERIALS AND METHODS: Comparative immunohistochemical analyses of different PD-L1 clones were performed on paraffin blocks of gastric adenocarcinoma surgical material from 39 patients who had not received chemotherapy, radiation, or immunotherapy preoperatively.

RESULTS: PD-L1 expression detected by the PBM-1A4 antibody clone was present in 46.2% of gastric cancer samples. Among PD-L1(PBM-1A4)-positive tumors, neoplasms of the second macroscopic type according to R. Bormann and tubular adenocarcinomas were significantly predominant. The SP142 clone showed the greatest consistency with PBM-1A4 expression (significant consistency, Cohen’s kappa = 0.67335).

CONCLUSION: Compared with the SP142 clone, the PBM-1A4 clone to PD-L1 during immunohistochemical examination on gastric adenocarcinoma material showed a close to identical immunological picture when. The data obtained appear promising for the use of the PBM-1A4 clone in the diagnosis of malignant neoplasms for patients with cancer, taking into account its economic component and accessibility.

Keywords

gastric cancer / PD-L1 / Russian clone

References

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. Corrected and republished from: CA Cancer J Clin. 2020;70(4):313. (In Russ.). doi: 10.3322/caac.21492

[2] Bray F., Ferlay J., Soerjomataram I., et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA Cancer J Clin. 2018. Vol. 68, N 6. P. 394–424. Corrected and republished from: CA Cancer J Clin. 2020. Vol. 70, N 4. P. 313. doi: 10.3322/caac.21492

[3] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. Corrected and republished from: CA Cancer J Clin. 2020;70(4):313. (In Russ.). doi: 10.3322/caac.21492

[4] Petrova GV, Gretsova OP, Starinsky VV. A comparison of the cancer incidence rates between the state cancer statistics and cancer registry data in the Russian Federation. Siberian Journal of Oncology. 2019;18(5):5–11. (In Russ.). EDN: LXIOLV doi: 10.21294/1814-4861-2019-18-5-5-11

[5] Петрова Г.В., Грецова О.П., Старинский В.В. Сравнение данных государственной онкологической статистики и ракового регистра России // Сибирский онкологический журнал. 2019. Т. 18, № 5. С. 5–11. EDN: LXIOLV doi: 10.21294/1814-4861-2019-18-5-5-11

[6] Petrova GV, Gretsova OP, Starinsky VV. A comparison of the cancer incidence rates between the state cancer statistics and cancer registry data in the Russian Federation. Siberian Journal of Oncology. 2019;18(5):5–11. (In Russ.). EDN: LXIOLV doi: 10.21294/1814-4861-2019-18-5-5-11

[7] Petrova GV, Starinsky VV, Gretsova OP, и др. Cancer care to the population of Russia in 2017 according to the data of federal statistical observation. P.A. Herzen Journal of Oncology. 2019;8(1):32–40. (In Russ.). EDN: ZCQTIL doi: 10.17116/onkolog2019801132

[8] Петрова Г.В., Старинский В.В., Грецова О.П., и др. Состояние онкологической помощи населению России в 2017 г. по данным федерального статистического наблюдения // Онкология. Журнал им. П.А. Герцена. 2019. Т. 8, № 1. С. 32–40. EDN: ZCQTIL doi: 10.17116/onkolog2019801132

[9] Petrova GV, Starinsky VV, Gretsova OP, и др. Cancer care to the population of Russia in 2017 according to the data of federal statistical observation. P.A. Herzen Journal of Oncology. 2019;8(1):32–40. (In Russ.). EDN: ZCQTIL doi: 10.17116/onkolog2019801132

[10] Caprin AD, Starinskiy VV, Khaylova ZhV, Shakhzadova AO. The comparative analysis of achieving the indicators of the regional projects “Control of oncological diseases” based on the real-time monitoring data in January-May 2018–2019. Vestnik Roszdravnadzora. 2019(4):64–71. (In Russ.). EDN: ZPNGGD doi: 10.35576/article_5d651dbc693279.10409311

[11] Каприн А.Д., Старинский В.В., Хайлова Ж.В., Шахзадова А.О. Сравнительный анализ выполнения индикаторов региональных проектов «Борьба с онкологическими заболеваниями» на основании данных оперативного мониторинга за период январь-май 2018–2019 гг. // Вестник Росздравнадзора. 2019. № 4. С. 64–71. EDN: ZPNGGD doi: 10.35576/article_5d651dbc693279.10409311

[12] Caprin AD, Starinskiy VV, Khaylova ZhV, Shakhzadova AO. The comparative analysis of achieving the indicators of the regional projects “Control of oncological diseases” based on the real-time monitoring data in January-May 2018–2019. Vestnik Roszdravnadzora. 2019(4):64–71. (In Russ.). EDN: ZPNGGD doi: 10.35576/article_5d651dbc693279.10409311

[13] Di Pinto F, Armentano R, Arborea G, et al. Are immunohistochemical markers useful in phenotypic gastric cancer classification? Oncology. 2020;98(8):566–574. doi: 10.1159/000506077

[14] Di Pinto F., Armentano R., Arborea G., et al. Are immunohistochemical markers useful in phenotypic gastric cancer classification? // Oncology. 2020. Vol. 98, N 8. P. 566–574. doi: 10.1159/000506077

[15] Di Pinto F, Armentano R, Arborea G, et al. Are immunohistochemical markers useful in phenotypic gastric cancer classification? Oncology. 2020;98(8):566–574. doi: 10.1159/000506077

[16] Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–1117. doi: 10.1016/s0140-6736(14)60958-2

[17] Robert C., Ribas A., Wolchok J.D., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial // Lancet. 2014. Vol. 384, N 9948. P. 1109–1117. doi: 10.1016/s0140-6736(14)60958-2

[18] Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–1117. doi: 10.1016/s0140-6736(14)60958-2

[19] Danilova NV, Sotnikova TN, Kalinin DV. PD-L1 expression in EBV-associated gastric carcinomas. Arkhiv patologii. 2022;84(4):5–12. (In Russ.). EDN: CPYSZS doi: 10.17116/patol2022840415

[20] Данилова Н.В., Сотникова Т.Н., Калинин Д.В., и др. Экспрессия PD-L1 в EBV-ассоциированном раке желудка // Архив патологии. 2022. Т. 84, № 4. С. 5–12. EDN: CPYSZS doi: 10.17116/patol2022840415

[21] Danilova NV, Sotnikova TN, Kalinin DV. PD-L1 expression in EBV-associated gastric carcinomas. Arkhiv patologii. 2022;84(4):5–12. (In Russ.). EDN: CPYSZS doi: 10.17116/patol2022840415

[22] Ma J, Li J, Qian M, et al. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28–8 and E1L3N). Diagn Pathol. 2018;13(1):91. doi: 10.1186/s13000-018-0766-0

[23] Ma J., Li J., Qian M., et al. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28–8 and E1L3N) // Diagn Pathol. 2018. Vol. 13, N 1. P. 91. doi: 10.1186/s13000-018-0766-0

[24] Ma J, Li J, Qian M, et al. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28–8 and E1L3N). Diagn Pathol. 2018;13(1):91. doi: 10.1186/s13000-018-0766-0

[25] Abdulzhaliev AT, Boulytcheva IV, Kovaleva OV, et al. PD-L1 and PU.1 expression in malignant peripheral nerve sheath tumors. Clinical and Experimental Morphology. 2023;12(2):44–53. (In Russ.). EDN: LMFJQQ doi: 10.31088/CEM2023.12.2.44-53

[26] Абдулжалиев А.Т., Булычева И.В., Ковалева О.В., и др. Экспрессия PD-L1 и PU.1 в злокачественных опухолях из оболочек периферических нервов // Клиническая и экспериментальная морфология. 2023. Т. 12, № 2. С. 44–53. EDN: LMFJQQ doi: 10.31088/CEM2023.12.2.44-53

[27] Abdulzhaliev AT, Boulytcheva IV, Kovaleva OV, et al. PD-L1 and PU.1 expression in malignant peripheral nerve sheath tumors. Clinical and Experimental Morphology. 2023;12(2):44–53. (In Russ.). EDN: LMFJQQ doi: 10.31088/CEM2023.12.2.44-53

[28] Sotnikova TN, Danilova NV, Polushkina TV, Kalinin DV. Association between PD-L1 status detected by SP142 and SP263 antibody clones and clinical and morphological features of gastric cancer factors. Journal of Anatomy and Histopathology. 2023;12(4):68–75. (In Russ.). EDN: MJHJQY doi: 10.18499/2225-7357-2023-12-4-68-75

[29] Сотникова Т.Н., Данилова Н.В., Полушкина Т.В., Калинин Д.В. Оценка связи PD-L1-статуса, выявляемого клонами SP142 и SP263, с клинико-морфологическими характеристиками рака желудка // Журнал анатомии и гистопатологии. 2023. Т. 12, № 4. С. 68–75. EDN: MJHJQY doi: 10.18499/2225-7357-2023-12-4-68-75

[30] Sotnikova TN, Danilova NV, Polushkina TV, Kalinin DV. Association between PD-L1 status detected by SP142 and SP263 antibody clones and clinical and morphological features of gastric cancer factors. Journal of Anatomy and Histopathology. 2023;12(4):68–75. (In Russ.). EDN: MJHJQY doi: 10.18499/2225-7357-2023-12-4-68-75

[31] Katona BW, Rustgi AK. Gastric cancer genomics: advances and future directions. Cell Mol Gastroenterol Hepatol. 2017;3(2):211–217. doi: 10.1016/j.jcmgh.2017.01.003

[32] Katona B.W., Rustgi A.K. Gastric cancer genomics: advances and future directions // Cell Mol Gastroenterol Hepatol. 2017. Vol. 3, N 2. P. 211–217. doi: 10.1016/j.jcmgh.2017.01.003

[33] Katona BW, Rustgi AK. Gastric cancer genomics: advances and future directions. Cell Mol Gastroenterol Hepatol. 2017;3(2):211–217. doi: 10.1016/j.jcmgh.2017.01.003

[34] Setia N, Agoston AT, Han HS, et al. A protein and mRNA expression-based classification of gastric cancer. Mod Pathol. 2016;29(7):772–784. doi: 10.1038/modpathol.2016.55

[35] Setia N., Agoston A.T., Han H.S., et al. A protein and mRNA expression-based classification of gastric cancer // Mod Pathol. 2016. Vol. 29, N 7. P. 772–784. doi: 10.1038/modpathol.2016.55

[36] Setia N, Agoston AT, Han HS, et al. A protein and mRNA expression-based classification of gastric cancer. Mod Pathol. 2016;29(7):772–784. doi: 10.1038/modpathol.2016.55

RIGHTS & PERMISSIONS

Eco-Vector